Lupin’s Corporate Quality Oversight Questioned In FDA Warning Letter

Two-month inspection during pandemic highlighted cross-contamination risks and process validation shortfalls at New Jersey plant.

Warning hazard sign and signage man falling
lupin warned again

The US Food and Drug Administration raised concerns about Lupin Limited’s overall corporate quality system in an 11 June warning letter concerning the company’s Novel Laboratories Inc. facility in Somerset, NJ.

The agency drew a connection between poor manufacturing practices observed at the plant during an eight-week inspection that concluded 5...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance